Research Interests
Study of autoimmune skin disease
Specialty autoimmune skin disease clinic 1 half day per week
Clinical retrospective studies, case series, and participation in clinical trials and regisitries for autoimmune skin disease including connective tissue disease, autoimmune blistering disease, and sarcoidosis
Principal Investigator on Viela Bio Duke IRB Pro00102079, Study Title: “A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren’s Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis
Subinvestigator on Duke IRB Pro00084622, Study Title “Retrospective Study evaluating cutaneous problems among immunocompromised patients (i.e. autoimmune disease, hematologic and solid organ malignancies and Hematopoetic Stem Cell Transplant (HSCT)”
Subinvestigator on Duke IRB Pro00048083, Study Title “Autoantibodies in Autoimmune Skin Disease”
Subinvestigator on Duke IRB Pro00106752, Study Title “Cutaneous Sarcoidosis Registry”
Subinvestigator on Duke IRB Pro00106917/ Pro00107123, Study Title “A Randomized, Double-Blinded, Placebo-Controlled Trial to Investigate the Efficacy, Safety, and Tolerability of Efgartigimod PH20 SC in Adult Patients With Pemphigus (Vulgaris or Foliaceus) (ADDRESS)”
Selected Grants
Multicenter, Open-Label, Single-Arm, Phase 3, Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of BIIB059 (Litifilimab) in Adult Participants with Active Subacute Cutaneous Lupus Erythematosus and/or Chronic Cutaneous Lupus Erythe
Clinical TrialPrincipal Investigator · Awarded by Biogen MA, Inc. · 2024 - 2029230LE301_Amethyst_
Clinical TrialPrincipal Investigator · Awarded by Biogen, Inc. · 2022 - 2025BMS-IM011-132-065
Clinical TrialPrincipal Investigator · Awarded by Bristol-Myers Squibb Company · 2022 - 2024ACE Covid 19 Admin. Supplement: Molecular Regulation of B cells and T cells in Human SLE - Cost Reimbursable
Clinical TrialCo Investigator · Awarded by Emory University · 2021 - 2024A Phase 1 Randomized, Placebo-Controlled, Blinded, Multiple Ascending Dose Study to Evaluate VIB 7734 in Systemic Lupus Erythematosus, Cutaneous Lupus Erythematosus, Sjogren¿s
Clinical TrialPrincipal Investigator · Awarded by Viela Bio, Inc. · 2019 - 2021External Relationships
- Argenx
- Biogen
- Bristol Myers Squibb
- Immunovant
This faculty member (or a member of their immediate family) has reported outside activities with the companies, institutions, or organizations listed above. This information is available to institutional leadership and, when appropriate, management plans are in place to address potential conflicts of interest.